Home Suppliers Feedback Search      GENTAUR HEADQUARTERS  +32 1641 4407  +32 1650 9045 

                                                                                                                                              mail: [email protected]




Rue Lagrange, 9

75005 Paris, France

 01 43 25 01 50



IME, Frockenbeckstrasse 6

52074 Aachen, Germany

 +32 1658 9045



23015 Milano, Italy

 02 36 00 65 93








Pegberon - Peginterferon alfa-2b injection, Y-shape





Pegberon® is the first 40kD PEG modified interferon alfa-2b medicine in the world, and it is indicated for chronic hepatitis C (CHC) and chronic hepatitis B (CHB). Comparing with other peginterferon alfa products modified by 12kD linear PEG or 40kD U-shape branched PEG in the market, Pegberon® has following advanced features:

      Exclusive international patent Y-shape branched PEG structure improves the drug stability;

      Pegylation by 40kD PEG strengthens the stability of serum drug concentration;

      Selective pegylation at high activity site results in higher antiviral activity;

      Lower incidence of neutralizing antibody brings higher possibility to achieve SVR.

To well assess its efficacy and safety, the clinical trials (phase I, II, III) of Pegberon® comparing with the launched peginteferon alfa-2a in CHC and CHB treatment have been finished in China.

      More than 2,000 patients are involved (CHC: >1,000 patients; CHB: >1,000 patients);

      The first macromolecular medicine which completed the head-to-head clinical comparative trials from phase I to phase III in China;

      The first genotyping clinical study for CHC treatment (phase III, N=770) in China;

      Till now the largest patient size (phase III, N=820) of registry clinical studies of peginterferon for CHB treatment in the world.

Besides, various quality studies and preclinical studies (pharmacodynamics, safety pharmacology, pharmacokinetics and toxicology) have been also finished in China.


Send mail to [email protected] with questions or comments about this web site.
Copyright © 2016 Gentaur
Last modified: 11/08/16